NYSE:EW - Edwards Lifesciences Stock Price, Price Target & More

Edwards Lifesciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "EW."

Edwards Lifesciences's stock split on the morning of Monday, December 14th 2015. The 2-1 split was announced on Thursday, November 19th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, December 11th 2015. An investor that had 100 shares of Edwards Lifesciences stock prior to the split would have 200 shares after the split.

Edwards Lifesciences declared that its Board of Directors has approved a stock repurchase program on Thursday, December 7th 2017, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase shares of its stock through open market purchases. Stock buyback programs are generally an indication that the company's board of directors believes its stock is undervalued.

Edwards Lifesciences Corp (NYSE:EW) issued its quarterly earnings data on Tuesday, April, 24th. The medical research company reported $1.22 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.11 by $0.11. The medical research company had revenue of $938 million for the quarter, compared to the consensus estimate of $936.69 million. Edwards Lifesciences had a return on equity of 28.60% and a net margin of 17.36%. The firm's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the company posted $0.94 earnings per share. View Edwards Lifesciences' Earnings History.

Edwards Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for Edwards Lifesciences.

Edwards Lifesciences updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $4.50-$4.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.53. The company issued revenue guidance of $3.5-$3.9 billion, compared to the consensus revenue estimate of $3.85 billion.Edwards Lifesciences also updated its Q2 guidance to $1.05-$1.15 EPS.

19 analysts have issued twelve-month price objectives for Edwards Lifesciences' shares. Their forecasts range from $115.00 to $180.00. On average, they expect Edwards Lifesciences' share price to reach $151.8750 in the next year. This suggests that the stock has a possible downside of 0.5%. View Analyst Ratings for Edwards Lifesciences.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Edwards Lifesciences in the last year. There are currently 4 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Edwards Lifesciences include Intuitive Surgical (ISRG), Align Technology (ALGN), Zimmer Biomet (ZBH), COLOPLAST A/S/ADR (CLPBY), Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), Steris (STE), Inogen (INGN), MSA Safety (MSA), Halyard Health (HYH), Wright Medical Group (WMGI), CONSORT Med PLC/S (CSRMY), Invacare (IVC), Sientra (SIEN) and RTI Surgical (RTIX).

Media coverage about EW stock has trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Edwards Lifesciences earned a news sentiment score of 0.21 on Accern's scale. They also assigned media stories about the medical research company an impact score of 45.61 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Edwards Lifesciences' stock is owned by a number of of institutional and retail investors. Top institutional investors include Hardman Johnston Global Advisors LLC (0.16%), Huntington National Bank (0.10%), Chicago Capital LLC (0.09%), Bank of Montreal Can (0.08%), Scout Investments Inc. (0.07%) and Calamos Advisors LLC (0.05%). Company insiders that own Edwards Lifesciences stock include Bernard J Zovighian, Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Dylan Sidoo, Huimin Wang, Jean-Luc M Lemercier, John T Cardis, Kieran Gallahue, Larry L Wood, Michael A Mussallem, Patrick B Verguet, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Institutional Ownership Trends for Edwards Lifesciences.

EW stock was sold by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., NN Investment Partners Holdings N.V., Bank of Montreal Can, Scout Investments Inc., Hardman Johnston Global Advisors LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Nippon Life Global Investors Americas Inc. and Hartford Investment Management Co.. Company insiders that have sold Edwards Lifesciences company stock in the last year include Catherine M Szyman, Donald E Bobo Jr, Donald E Bobo, Jr, Huimin Wang, Jean-Luc M Lemercier, Larry L Wood, Michael A Mussallem, Robert WA Sellers, Schack Wesley W Von, Scott B Ullem and William J Phd Link. View Insider Buying and Selling for Edwards Lifesciences.

EW stock was bought by a variety of institutional investors in the last quarter, including Cornerstone Wealth Management LLC, Handelsbanken Fonder AB, Chicago Capital LLC, Huntington National Bank, Calamos Advisors LLC, Sit Investment Associates Inc., State of Alaska Department of Revenue and Patten & Patten Inc. TN. Company insiders that have bought Edwards Lifesciences stock in the last two years include Catherine M Szyman, Dylan Sidoo and Kieran Gallahue. View Insider Buying and Selling for Edwards Lifesciences.

Shares of EW can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of EW stock can currently be purchased for approximately $152.62.

Edwards Lifesciences has a market capitalization of $32.17 billion and generates $3.44 billion in revenue each year. The medical research company earns $583.60 million in net income (profit) each year or $3.80 on an earnings per share basis. Edwards Lifesciences employs 12,200 workers across the globe.

Edwards Lifesciences' mailing address is ONE EDWARDS WAY, IRVINE CA, 92614. The medical research company can be reached via phone at 949-250-2500 or via email at [email protected]